慢性肝病靶样原发性肝脏恶性肿瘤:术前MRI联合临床因素预测术后生存
多中心回顾性研究纳入197例慢性肝病伴单发靶样原发性肝脏恶性肿瘤患者,术前行钆塞酸增强MRI并接受根治性手术。基于肿瘤大小、环形动脉期高强化、静脉瘤栓及肝胆期低信号结节等构建复发和总生存风险评分,外部验证C指数0.62-0.76,可将患者分为预后良好、中等和差三组。
要点
- 靶样肝脏恶性肿瘤术前MRI示环形动脉期高强化、肿瘤>5cm、静脉瘤栓提示术后复发和生存更差。
- 肝胆期无动脉期高强化的低信号结节也纳入复发风险模型,需在报告中关注。
- 风险评分将患者分为良好、中等、差三组,生存曲线差异有统计学意义。
关键影像表现/征象
- 靶样原发性肝脏恶性肿瘤在术前钆塞酸增强MRI上表现为异质性靶样病变。
- 环形动脉期高强化(thin-rim APHE)是复发和总生存风险模型纳入的影像特征。
- 肿瘤大小2-5cm或>5cm、静脉瘤栓(TIV)及非TIV的肿瘤血管侵犯纳入风险模型。
- 肝胆期无动脉期高强化的低信号结节(HBP hypointense nodules without APHE)纳入复发模型2。
诊断标准与关键数值
- RFS模型1纳入肿瘤大小2-5cm或>5cm及薄环动脉期高强化,剔除仅肝胆期可获取的特征。
- RFS模型2纳入肿瘤>5cm、静脉瘤栓及肝胆期无动脉期高强化的低信号结节。
- OS模型纳入肿瘤>5cm、薄环动脉期高强化、静脉瘤栓及非静脉瘤栓的肿瘤血管侵犯。
- 外部验证队列C指数0.62-0.76,风险评分将患者分为良好、中等、差三组,组间生存差异log-rank p<0.05。
临床应用与阅片要点
- 阅片时需评估靶样病变的环形动脉期强化模式、肿瘤大小、静脉瘤栓及肝胆期低信号结节。
- 报告应明确描述血管侵犯状态(包括静脉瘤栓和非静脉瘤栓的肿瘤血管侵犯),以支持术后风险分层。
- 对于慢性肝病伴靶样肝脏恶性肿瘤患者,可结合MRI特征和临床因素使用风险评分辅助预测术后生存。
局限性
- 回顾性研究设计。
- 样本量有限(197例),外部验证队列仅77例。
- 风险评分外部验证C指数0.62-0.76,判别能力中等。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVE: We aimed to assess and validate the radiologic and clinical factors that were associated with recurrence and survival after curative surgery for heterogeneous targetoid primary liver malignancies in patients with chronic liver disease and to develop scoring systems for risk stratification.
MATERIALS AND METHODS: This multicenter retrospective study included 197 consecutive patients with chronic liver disease who had a single targetoid primary liver malignancy (142 hepatocellular carcinomas, 37 cholangiocarcinomas, 17 combined hepatocellular carcinoma-cholangiocarcinomas, and one neuroendocrine carcinoma) identified on preoperative gadoxetic acid-enhanced MRI and subsequently surgically removed between 2010 and 2017. Of these, 120 patients constituted the development cohort, and 77 patients from separate institution served as an external validation cohort. Factors associated with recurrence-free survival (RFS) and overall survival (OS) were identified using a Cox proportional hazards analysis, and risk scores were developed. The discriminatory power of the risk scores in the external validation cohort was evaluated using the Harrell C-index. The Kaplan-Meier curves were used to estimate RFS and OS for the different risk-score groups.
RESULTS: In RFS model 1, which eliminated features exclusively accessible on the hepatobiliary phase (HBP), tumor size of 2-5 cm or > 5 cm, and thin-rim arterial phase hyperenhancement (APHE) were included. In RFS model 2, tumors with a size of > 5 cm, tumor in vein (TIV), and HBP hypointense nodules without APHE were included. The OS model included a tumor size of > 5 cm, thin-rim APHE, TIV, and tumor vascular involvement other than TIV. The risk scores of the models showed good discriminatory performance in the external validation set (C-index, 0.62-0.76). The scoring system categorized the patients into three risk groups: favorable, intermediate, and poor, each with a distinct survival outcome (all log-rank p < 0.05).
CONCLUSION: Risk scores based on rim arterial enhancement pattern, tumor size, HBP findings, and radiologic vascular invasion status may help predict postoperative RFS and OS in patients with targetoid primary liver malignancies.
引用
- Park, Heo, Kim, et al. Targetoid Primary Liver Malignancy in Chronic Liver Disease: Prediction of Postoperative Survival Using Preoperative MRI Findings and Clinical Factors. Korean J Radiol. 2023. PMID: 36788766. doi:10.3348/kjr.2022.0560
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。